Trastuzumab deruxtecan shows limited efficacy in HER2-positive breast squamous cell carcinoma following standard therapy failure
New Treatment Options for Rare HER2-Positive Breast Squamous Cell Carcinoma
This case report and literature review examines the management of a patient with HER2-positive primary breast squamous cell carcinoma. The a…
A rare form of breast cancer may respond differently to standard treatments, highlighting the need for personalized medicine based on specif…
Pyrotinib-based regimen achieves pathological complete response after non-response to standard neoadjuvant therapy in HER2+ breast cancer
Case shows new drug combo may help breast cancer patient
This case report and literature review describes a patient with HER2+/HR+ breast cancer who achieved total pathological complete response af…
A woman with HER2-positive breast cancer achieved complete response after switching to a pyrotinib-based regimen when standard therapy faile…
Trastuzumab deruxtecan and pyrotinib provide disease control in lung squamous cell carcinoma with ERBB2 mutation
New Treatment Strategy Shows Promise for Lung Squamous Cell Carcinoma
This case report describes a patient with stage IA2 lung squamous cell carcinoma and an ERBB2 exon 20 p.G776V mutation treated with trastuzu…
A new treatment plan using trastuzumab deruxtecan and pyrotinib showed promising results for a patient with a specific lung cancer mutation.